Published in Oncoimmunology on April 22, 2016
M3 Macrophages Stop Division of Tumor Cells In Vitro and Extend Survival of Mice with Ehrlich Ascites Carcinoma. Med Sci Monit Basic Res (2017) 0.75
A review of the importance of immune responses in luminal B breast cancer. Oncoimmunology (2017) 0.75
Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma. Transl Lung Cancer Res (2017) 0.75
Inflammation and cancer. Nature (2002) 53.78
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol (1981) 12.96
Macrophage activation and polarization. Front Biosci (2008) 11.17
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med (2007) 7.87
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res (2010) 4.25
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2007) 3.95
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood (2005) 3.85
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res (2006) 2.76
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol (2006) 2.67
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res (2003) 2.50
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol (2009) 2.14
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 1.92
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice. J Clin Invest (2009) 1.87
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J (2009) 1.70
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol (2003) 1.62
Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev (1997) 1.43
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer (2010) 1.43
A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol (2011) 1.41
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer (2012) 1.39
CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol (2005) 1.34
T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res (1999) 1.28
Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys (2007) 1.28
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
F4/80 and the related adhesion-GPCRs. Eur J Immunol (2011) 1.20
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol (2008) 1.19
Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol (2012) 1.17
Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther (2008) 1.14
Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood (1989) 1.12
HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res (2014) 1.09
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol (1999) 1.09
Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer (2011) 1.06
Macrophages promote tumour growth and liver metastasis in an orthotopic syngeneic mouse model of colon cancer. Int J Colorectal Dis (2013) 1.04
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res (2005) 1.02
Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo. Immunology (1989) 1.00
Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice. Aging Cell (2013) 0.97
Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas. Front Immunol (2014) 0.94
CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol (2010) 0.91
Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses. Cancer Immunol Immunother (2011) 0.90
Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur Respir J (2009) 0.90
Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis. Mol Cancer (2013) 0.89
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res (2002) 0.89
Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol (2011) 0.89
Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol (2007) 0.89
Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol (1998) 0.85
IL-2 induces expression and secretion of IFN-gamma in murine peritoneal macrophages. J Leukoc Biol (2005) 0.83
Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution. Cancer Gene Ther (2010) 0.79
IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice. Age (Dordr) (2014) 0.76
Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance. Clin Cancer Res (2001) 0.76